SII to increase Covishield production to 200 million volumes per month from October

SII to increase Covishield production to 200 million volumes per month from October

SII to increase Covishield production to 200 million volumes per month from October: Adar Poonawalla and Kiran Mazumdar Shaw, executive chairman, Biocon and Biocon Biologics (BBL) spoke at a press conference on Friday to announce their strategic alliance.
ADAR POONAWALLA, chief executive of the Serum Institute of India (SII), on Friday said they were building a mRNA drug development center, even though SII was increasing its production of Covishield vaccines from the current 160 million doses per month to 200 million from October.

While the mRNA vaccine center will take two years to complete, the infrastructure will be available to two companies – Serum Institute Life Sciences Limited (SILS) and Biocon Biologics Limited – which have recently entered into a long-term partnership.

Poonawalla and Kiran Mazumdar Shaw, executive chairman, Biocon and Biocon Biologics (BBL) spoke at a press conference on Friday to announce their strategic alliance. trading rights for SILS vaccine portfolio of global markets. SILS will receive about 15 percent of the BBL, according to an estimated $ 4.9 billion. This alliance will allow us to combine our efforts in biologics and vaccines to have a positive impact on the fight against infectious diseases. In addition to vaccines, the coalition will also build antibodies against many infectious diseases such as dengue and HIV, ”said Shaw.

Poonawalla said within the framework of the partnership, there are many opportunities to explore, for example, mRNA technology… creating an environment that will serve at least 100 million volumes – this will take two years to build but until then, BBL does its research and finds products, we can do and share profits. These are additions that will take place over the years. There are limitations to mRNA technology related to long-term performance. If we start with someone who will be prescribed mRNA, it should be at a stable temperature of 2 to 8 degrees and not 70 degrees, ”Poonawalla said in response to a question. alliance now. “We have known each other for decades and there has never been a time when the world has the greatest potential for using our production and research skills. In 2020, I had to make a difficult decision where I had to temporarily put down our monoclonals and power plans. All that was donated by producing Covishield prices. We produce and deliver 160 million Covishield doses every month to the country. This will soon be expanded to 200 million doses from October. We now hope to keep our ambitions in place of living things, ”he said.

Increasing the production rate to 200 million Covishield volumes per month will also be based on the raw material acquired by SII from the raw material acquisition list. Poonawalla said there had been improvements since March in supply supplies.

According to Shaw, they had a strong desire for independence. “We do not want to disrupt procurement and therefore efforts to build the entire inventory in the country. We don’t have to rely on foreign suppliers, that’s what Adar feels about, ”said Shaw. “We will now discuss and examine the most common consumer goods and list four or five major items – reusable bags and others where the focus strategy can be implemented,” Poonawalla said.

With the export restrictions lifted, Poonawalla hoped it would subside within the next two months. “Given the fact that we have brought so many vaccines and others in India that we have delivered, we are very close to where there is enough stock of vaccines especially now as we move forward this year. Over the next two months, we expect a slight drop in export restrictions. However, we will go with what the GoI thinks is appropriate as they need to balance the placement of vaccines in the event of the third and fourth waves to come. Taking the lessons we learned from the second wave that hit India so badly, we do not want to be in that situation and that is why the Indian government is careful to control the stock of vaccines, ”said Poonawalla.

In booster shots, Poonawalla said the judges are still out of the case. “There is no evidence that so far Covishield needs a third dose – some people who want to take it may have taken this dose. We do not officially recommend it and DCGI and ICMR will have to decide, including how effective the vaccine is in delta diversity. Some Western vaccines have reported a decrease in antibody response which is why they recommend a third dose.

However, the main purpose is to give both doses to all people and to consider the third dose as an incentive as it is unreasonable to give a third dose when others in certain countries and individuals have not been given two doses. While only 2 to 3 percent of the world’s developing countries have received vaccines, they have increased to 40-50% in developed countries.

Wealthy nations have taken many goals and are talking about giving the wrong third dose until a significant portion of other countries get two doses. Until then we can look at the booster shot that will eventually take place, from a moral point of view we should focus on strategies in this way, ”he said.

Asked if the full immunization of all eligible beneficiaries in India by the end of the year was unattainable, Poonawalla said she did not want to speculate. “Everyone with this disease I think has regretted making statements. So I don’t want to guess. We will be providing 200 million doses from October. Barat Biotech was growing more.

Leave a Reply

Your email address will not be published. Required fields are marked *

Open chat